BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Nasdaq/NYSE listing notice — Brainstorm Cell Nasdaq delisting risk: MVLS below $35M minimum

BRAINSTORM CELL THERAPEUTICS INC.

Received Nasdaq deficiency notice on Nov 6, 2023 for MVLS below $35M required for continued listing.
Has 180 calendar days, until May 6, 2024, to regain compliance; must close at $35M+ for 10 consecutive days.
Common stock continues trading under symbol BCLI on Nasdaq Capital Market during compliance period.
Company intends to take reasonable measures to regain compliance but no assurance of success.
If not compliant by May 6, 2024, Nasdaq may delist; appeal possible but uncertain.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

November 6, 2023, Brainstorm Cell Therapeutics Inc. (the “Company”) received a letter (the “MVLS Deficiency Notice”) from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that from September 25, 2023 to November 3, 2023, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). The MVLS Deficiency Notice has no immediate effect on the listing of the Company’s comm

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-116254

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.